Recent Updates
Recently added Catalysts
PLSE Positive Sentiment

Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026

Thursday, October 8, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Pulse Biosciences, Inc. announced that its nPulse technology will be featured at the 21st Annual International Ventricular Arrhythmias Symposium in 2026. The event will take place in New York on October 9-10, where preclinical applications of the nPulse prototypes will be presented. This highlights the company's ongoing innovation in the field of nanosecond pulsed field ablation.

Market Sentiment Analysis

POSITIVE FACTORS

  • Pulse Biosciences' nPulse technology shows promising advancements.
  • The technology will be showcased at a significant international symposium.
  • Preclinical applications indicate potential for future clinical use.

Full Press Release Details

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced the latest nPulse™ technology advancement will be featured during the 21st Annual International Ventricular Arrhythmias (VT) Symposium 2026, taking place October 9-10 in New York. A presentation at the Symposium will feature preclinical applications of two nPulse prototype endoc

Frequently Asked Questions

What is the nPulse technology?

nPulse technology is Pulse Biosciences' proprietary nanosecond pulsed field ablation technology.

When is the VT Symposium 2026 taking place?

The VT Symposium 2026 will occur on October 9-10 in New York.

What will be presented at the symposium?

The symposium will feature preclinical applications of two nPulse prototype endoc.

Who is showcasing the nPulse technology?

Pulse Biosciences, Inc. is showcasing the nPulse technology at the symposium.

ShareAdd on Google
Tags: PLSE Pulse Biosciences nPulse VT Symposium nanosecond pulsed field ablation
Last updated: Oct 8, 2026

Biotech snapshot

Cash runway
$102M liquidity · $6M/mo burn
~14 mo
Low dilution risk